TxCell to lead POSITIVE project to automate first production step of Ovasave personalised cellular immunotherapy

Grant of over EUR 400,000 awarded by the Conseil Régional Provence-Alpes-Côte-D’azur to the consortium of TxCell, Gene and Cell therapy Unit, Nice (UTCG) and Biosafe

07-Jul-2014 - France

TxCell SA announced the launch of, and funding awarded to, the POSITIVE project in collaboration with the Gene and Cell therapy Unit (UTCG) developing new antiviral cell-based immunotherapies and Biosafe, a Swiss private company, a developer of innovative solutions for cell processing.

The POSITVE project will focus on the development and establishment of a procedure to automate the first step of manufacturing of Ovasave(R), TxCell’s lead innovative, personalized cellular immunotherapy for severe refractory Crohn’s disease patients. Biosafe’s Sepax system will enable the automated and standardized separation of mononuclear white blood cells for the production of cellular immunotherapy.

This collaborative project, accredited by the French competitive cluster Eurobiomed, is supported by APRF funding (Appel à Projet Recherche Finalisée), from the Conseil Régional Provence-Alpes-Côte-D’azur. The grant totals EUR 417,000, of which TxCell will receive a grant of EUR 250,000 and UTCG will receive EUR 167,000. Both grants will be for the performance of experiments by TxCell and UTCG and the optimization of the resulting new automated and standardized procedure. Biosafe will also utilise its Sepax technology expertise and know-how to optimize the dedicated software and protocol.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances